Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (Mpro, 3CLpro) and papain-like protease (PLpro) are responsible for viral polyprotein cleavage-a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2H)-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and antiviral assays. In this study, we screened a collection of 34 ebselen and ebselen diselenide derivatives for SARS-CoV-2 PLpro and Mpro inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PLpro and four Mpro inhibitors superior to ebselen. Independently, ebselen was shown to inhibit the N7-methyltransferase activity of SARS-CoV-2 nsp14 protein involved in viral RNA cap modification. Hence, selected compounds were also evaluated as nsp14 inhibitors. In the second part of our work, we employed 11 ebselen analogues-bis(2-carbamoylaryl)phenyl diselenides-in biological assays to evaluate their anti-SARS-CoV-2 activity in Vero E6 cells. We present their antiviral and cytoprotective activity and also low cytotoxicity. Our work shows that ebselen, its derivatives, and diselenide analogues constitute a promising platform for development of new antivirals targeting the SARS-CoV-2 virus.

Centre of New Technologies University of Warsaw Banacha 2C 02 097 Warsaw Poland

College of Inter Faculty Individual Studies in Mathematics and Natural Sciences University of Warsaw Banacha 2C 02 097 Warsaw Poland

Department of Biochemistry and Structural Biology University of Texas Health Science Center at San Antonio San Antonio TX 78229 USA

Department of Chemical Biology and Bioimaging Wroclaw University of Science and Technology Wyb Wyspianskiego 27 50 370 Wroclaw Poland

Department of Organic and Medicinal Chemistry Faculty of Chemistry Wroclaw University of Science and Technology Wyb Wyspianskiego 27 50 370 Wroclaw Poland

German Center for Infection Research Hamburg Lübeck Borstel Riems Site University of Lübeck 23562 Lübeck Germany

Institute of Molecular Medicine University of Lübeck Ratzeburger Allee 160 23562 Lübeck Germany

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo Nám 2 16610 Prague Czech Republic

National Medicines Institute Ul Chełmska 30 34 00 725 Warsaw Poland

000      

00000naa a2200000 a 4500

001      

bmc23011102

003      

CZ-PrNML

005      

20230801132816.0

007      

ta

008      

230718s2023 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1038/s41598-023-35907-w $2 doi

035    __

$a (PubMed)37280236

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Zmudzinski, Mikolaj $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland. mikolaj.zmudzinski@pwr.edu.pl

245    10

$a Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase / $c M. Zmudzinski, W. Rut, K. Olech, J. Granda, M. Giurg, M. Burda-Grabowska, R. Kaleta, M. Zgarbova, R. Kasprzyk, L. Zhang, X. Sun, Z. Lv, D. Nayak, M. Kesik-Brodacka, SK. Olsen, J. Weber, R. Hilgenfeld, J. Jemielity, M. Drag

520    9_

$a Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (Mpro, 3CLpro) and papain-like protease (PLpro) are responsible for viral polyprotein cleavage-a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2H)-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and antiviral assays. In this study, we screened a collection of 34 ebselen and ebselen diselenide derivatives for SARS-CoV-2 PLpro and Mpro inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PLpro and four Mpro inhibitors superior to ebselen. Independently, ebselen was shown to inhibit the N7-methyltransferase activity of SARS-CoV-2 nsp14 protein involved in viral RNA cap modification. Hence, selected compounds were also evaluated as nsp14 inhibitors. In the second part of our work, we employed 11 ebselen analogues-bis(2-carbamoylaryl)phenyl diselenides-in biological assays to evaluate their anti-SARS-CoV-2 activity in Vero E6 cells. We present their antiviral and cytoprotective activity and also low cytotoxicity. Our work shows that ebselen, its derivatives, and diselenide analogues constitute a promising platform for development of new antivirals targeting the SARS-CoV-2 virus.

650    _2

$a lidé $7 D006801

650    12

$a SARS-CoV-2 $x metabolismus $7 D000086402

650    12

$a COVID-19 $7 D000086382

650    _2

$a methyltransferasy $7 D008780

650    _2

$a proteasy $7 D010447

650    _2

$a antivirové látky $x farmakologie $x metabolismus $7 D000998

650    _2

$a cysteinové endopeptidasy $x metabolismus $7 D003546

650    _2

$a inhibitory proteas $x farmakologie $7 D011480

650    _2

$a simulace molekulového dockingu $7 D062105

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a Research Support, N.I.H., Extramural $7 D052061

700    1_

$a Rut, Wioletta $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland

700    1_

$a Olech, Kamila $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland

700    1_

$a Granda, Jarosław $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland

700    1_

$a Giurg, Mirosław $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland

700    1_

$a Burda-Grabowska, Małgorzata $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland

700    1_

$a Kaleta, Rafał $u Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland

700    1_

$a Zgarbova, Michala $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague, Czech Republic

700    1_

$a Kasprzyk, Renata $u Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097, Warsaw, Poland $u College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, Banacha 2C, 02-097, Warsaw, Poland

700    1_

$a Zhang, Linlin $u Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany

700    1_

$a Sun, Xinyuanyuan $u Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany

700    1_

$a Lv, Zongyang $u Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA

700    1_

$a Nayak, Digant $u Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA

700    1_

$a Kesik-Brodacka, Malgorzata $u National Medicines Institute, Ul. Chełmska 30/34, 00-725, Warsaw, Poland

700    1_

$a Olsen, Shaun K $u Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA

700    1_

$a Weber, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague, Czech Republic

700    1_

$a Hilgenfeld, Rolf $u Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany $u German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, University of Lübeck, 23562, Lübeck, Germany

700    1_

$a Jemielity, Jacek $u Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097, Warsaw, Poland

700    1_

$a Drag, Marcin $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370, Wroclaw, Poland. marcin.drag@pwr.edu.pl

773    0_

$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 9161

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37280236 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230718 $b ABA008

991    __

$a 20230801132813 $b ABA008

999    __

$a ok $b bmc $g 1963479 $s 1197367

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 13 $c 1 $d 9161 $e 20230606 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195

GRA    __

$a R01 GM128731 $p NIGMS NIH HHS $2 United States

GRA    __

$a R01 GM115568 $p NIGMS NIH HHS $2 United States

LZP    __

$a Pubmed-20230718